Gypenoside XLIX Ameliorate High-Fat Diet-Induced Atherosclerosis via Regulating Intestinal Microbiota, Alleviating Inflammatory Response and Restraining Oxidative Stress in ApoE-/- Mice

doi:10.3390/ph15091056

科研成果详情

题名	Gypenoside XLIX Ameliorate High-Fat Diet-Induced Atherosclerosis via Regulating Intestinal Microbiota, Alleviating Inflammatory Response and Restraining Oxidative Stress in ApoE-/- Mice
作者	Gao, Ming 1,2; Heng, Xing 1; Jin, Jing 3; Chu, Weihua 1
发表日期	2022-09
发表期刊	Pharmaceuticals (Basel, Switzerland) 影响因子和分区
语种	英语
原始文献类型	Article
关键词	atherosclerosis gut microbiota gypenoside XLIX inflammation metabolism
其他关键词	GUT MICROBIOTA ; HEALTH
摘要	A high-fat choline diet (HFCD)-induced atherosclerosis model in ApoE-/- mice was established to explore the anti-atherosclerotic effects of gypenoside XLIX (GPE). It was found that HFCD-induced atherosclerotic index such as dyslipidemia, atherosclerotic plaque, inflammation, and gut microbiota dysfunction could be reduced by GPE treatment. GPE treatment could decrease Verrucomicrobia, Proteobacteria, and Actinobacteria abundance, and increase Firmicutes and Bacteroidetes population. Moreover, the Firmicutes/Bacteroidetes ratio increased significantly after treatment with GPE. After treatment with GPE, the relative abundance of trimethylamine-producing intestinal bacteria Clostridioides and Desulfovibrionaceae decreased while butyrate-producing bacteria such as Eubacterium, Roseburia, Bifidobacterium, Lactobacillus, and Prevotella increased significantly. The GPE group demonstrated higher SCFAs concentrations in the fecal sample, such as Acetic Acid, Propionic Acid, and Butyric Acid. Further pathway analysis showed that 29 metabolic pathways were appreciably disturbed during GPE treatment, including citrate cycle (TCA cycle); galactose and glycero-lipid-metabolism biosynthesis of unsaturated fatty acids, fatty acid biosynthesis. This study suggests that the anti-atherosclerotic effect of GPE is related to the substantial changes in intestinal microbiota and anti-inflammatory activity
资助项目	Priority Academic Program Development of Jiangsu Higher Education Institutions[PAPD];Key Discipline Project of Lishui City, Zhejiang Province, China[2021GYX21];
出版者	MDPI
出版地	BASEL
ISSN	1424-8247
EISSN	1424-8247
卷号	15 期号:9
DOI	10.3390/ph15091056
页数	15
WOS类目	Chemistry, Medicinal ; Pharmacology & Pharmacy
WOS研究方向	Pharmacology & Pharmacy
WOS记录号	WOS:000858700100001
收录类别	PUBMED ; SCIE ; SCOPUS
URL	查看原文
PubMed ID	36145277
SCOPUSEID	2-s2.0-85138600664
通讯作者地址	[Chu, Weihua]State Key Laboratory of Natural Medicines,School of Life Science and Technology,China Pharmaceutical University,Nanjing,210009,China
Scopus学科分类	Molecular Medicine;Pharmaceutical Science;Drug Discovery
引用统计	被引频次[WOS]：0 [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/166720
专题	第一临床医学院（信息与工程学院）、附属第一医院附属第一医院
通讯作者	Chu, Weihua
作者单位	1.State Key Laboratory of Natural Medicines,School of Life Science and Technology,China Pharmaceutical University,Nanjing,210009,China; 2.Nanjing Zhiyi Biotechnology Co.,Ltd,Nanjing,210014,China; 3.The People’s Hospital of Lishui,The Sixth Affiliated Hospital of Wenzhou Medical University,The First Affiliated Hospital of Lishui University,Lishui,323050,China
推荐引用方式 GB/T 7714	Gao, Ming,Heng, Xing,Jin, Jing,et al. Gypenoside XLIX Ameliorate High-Fat Diet-Induced Atherosclerosis via Regulating Intestinal Microbiota, Alleviating Inflammatory Response and Restraining Oxidative Stress in ApoE-/- Mice[J]. Pharmaceuticals (Basel, Switzerland),2022,15(9).
APA	Gao, Ming, Heng, Xing, Jin, Jing, & Chu, Weihua. (2022). Gypenoside XLIX Ameliorate High-Fat Diet-Induced Atherosclerosis via Regulating Intestinal Microbiota, Alleviating Inflammatory Response and Restraining Oxidative Stress in ApoE-/- Mice. Pharmaceuticals (Basel, Switzerland), 15(9).
MLA	Gao, Ming,et al."Gypenoside XLIX Ameliorate High-Fat Diet-Induced Atherosclerosis via Regulating Intestinal Microbiota, Alleviating Inflammatory Response and Restraining Oxidative Stress in ApoE-/- Mice".Pharmaceuticals (Basel, Switzerland) 15.9(2022).